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Abstract: Antiretroviral fixed-dose combination (FDC ARV) has been used in HIV 
patient therapy. The therapy is recommended to be monitored using a viral load 
(VL), reflecting the amount of HIV in the blood. Since 2015, the VL testing has 
been carried out at Pengayoman Cipinang Hospital. However, the evaluation of 
adherence to the FDC antiretroviral therapy on VL has never been conducted. This 
study aims to determine the relationship between the adherence level to the FDC 
ARVs and VL at Pengayoman Cipinang Hospital in 2015-2018. The study used a 
cross-sectional design and a random sampling technique. The sample size was 70, 
and data generated from the medical record. Kruskal Wallis test showed no 
differences in the level of adherence in the group based on gender, education level, 
marital status, employment status, and the risk factor for HIV. However, there was 
a significant difference in the age group. Cross-tab data showed virological failure 
(VL> 400 copies/ml) was found in 1.8% of patients with good adherence, 75% of 
patients with moderate adherence, and 100% of patients with poor adherence. The 
Chi-square test showed a significant relationship between adherence to FDC ARV 
and VL (p=0.000). It can be concluded that there was a significant relationship 
between the level of adherence in taking ARV FDC and viral load. 
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Abstrak: Kombinasi dosis tetap antiretroviral (FDC ARV) telah digunakan dalam terapi 
pasien HIV. Terapi ini direkomendasikan untuk dipantau menggunakan viral load (VL), 
yang mencerminkan jumlah HIV dalam darah. Sejak 2015, pengujian VL telah dilakukan 
di Rumah Sakit Pengayoman Cipinang. Namun, evaluasi kepatuhan terhadap terapi 
antiretroviral FDC pada VL belum pernah dilakukan. Penelitian ini bertujuan untuk 
mengetahui hubungan antara tingkat kepatuhan terhadap ARV FDC dan VL di Rumah 
Sakit Pengayoman Cipinang pada 2015-2018. Penelitian ini menggunakan desain cross-
sectional dan teknik pengambilan sampel acak. Ukuran sampel adalah 70, dan data 
didapatkan dari rekam medis. Tes Kruskal Wallis menunjukkan tidak ada perbedaan 
tingkat kepatuhan berdasarkan jenis kelamin, tingkat pendidikan, status perkawinan, status 
pekerjaan, dan faktor risiko untuk HIV. Namun, ada perbedaan signifikan kepatuhan pada 
kelompok umur. Data lintas-tab menunjukkan kegagalan virologi (VL> 400) ditemukan 
pada 1,8% pasien dengan kepatuhan yang baik, 75% pasien dengan kepatuhan sedang, dan 
100% pasien dengan kepatuhan buruk. Uji Chi-square menunjukkan hubungan yang 
signifikan antara kepatuhan terhadap ARV FDC dan VL (p=0,000). Dapat disimpulkan 
bahwa ada hubungan yang signifikan antara tingkat kepatuhan dalam mengambil ARV 
FDC dan viral load.  
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INTRODUCTION 
 
Based on data from the World Health 
Organization in 2017,1 there are 36.9 million people 
infected with the Human Immunodeficiency Virus 
(HIV), where 0.8% of them are between 15-49 years 
old. In Indonesia, the number of new cases of HIV 
infection continues to rise. Based on the report 
from January-March in 2017, there were 10,376 HIV-
infected people with a cumulative amount of 242 
699 people. Jakarta is the province which ranks first 
with a total of 46.758 HIV-infected people.1 
Human Immunodeficiency Virus is a retrovirus 
that infects CD4 T cells and macrophages, which are 
vital components of the immune system. People 
living with HIV/AIDS (PLWHA) have a weak immune 
system that they are likely to be susceptible to 
opportunistic infections. Therefore, PLWHA must 
take antiretroviral drugs (ARVs) to maintain their 
immune system.  It is required to have a high level 
of adherence in taking antiretroviral drugs to have 
good virological suppression. Adherence is defined 
as routinely taking drugs based on medical 
prescriptions. Adherence to taking ARV drugs is the 
most important factor in reducing the number of 
HIV viruses. The prolonged stable suppression of 
the amount of virus aims to keep the body's 
immune at a high level.2 The result shows that to 
achieve optimal levels of viral suppression, at least 
95% of all doses must be fulfilled.3 
Based on the result, it reveals that the simpler 
the ARV drug regimen is, the higher the level of the 
patients’ adherence in taking ARV drugs will be.4 
Since 2012, Pengayoman Cipinang Hospital has been 
utilizing antiretroviral fixed-dose combination (FDC) 
at the first-line. The drug consists of two nucleoside 
reverse transcriptase inhibitors   (NRTIs), such as 
Tenofovir (TDF) and Lamivudine (3TC) and one non-
nucleoside reverse transcriptase inhibitors 
(NNRTIs), such as Efavirenz (EFV).  The combination 
of these drugs works to inhibit reverse 
transcriptase so that HIV RNA cannot be 
transcribed into DNA and entered into the host cell 
genome.5 HIV patients only need to take FDC 
ARV once. The treatment using FDC ARVs is the best 
therapy for HIV patients currently. The main 
purpose of ARV treatment is to reduce viral load 
and that the immune status of HIV patients 
increases, to reduce mortality risk from 
opportunistic infections, and to reduce the risk of 
transmission.5,6     
The success of ARV therapy is suggested to be 
monitored using a viral load that reflects the 
amount of HIV in the blood. When the test result 
shows HIV RNA of 20,000 copies/ml, it indicates 
that there are 10,000 virus particles in every 
milliliter of blood as each HIV carries two copies of 
RNA. The result of the test shows that the 
measurement of viral load on the magnitude of the 
replication of the virus is better than examining T-
CD4 lymphocyte cell levels to predict the 
progression of HIV infection. Examination of the 
viral load of HIV is used to determine the 
effectiveness or failure of antiretroviral therapy.7,8   
Since 2015, viral load testing has been carried 
out at Pengayoman Cipinang Hospital using 
GeneXpert® Dx technology. The tool can 
automatically extract nucleic acids, perform 
amplification, and detect nucleic acid sequences 
using real-time reverse transcriptase-polymerase 
chain reaction (RT-PCR).9 Evaluation of adherence 
to taking first-line FDC ARV drugs and their 
effectiveness in suppressing viral load has never 
been conducted in HIV patients at Pengayoman 
Cipinang Hospital. Based on this rationale, a study 
was conducted to determine the relationship 
between the level of adherence in taking first-line 
ARV FDC drugs and viral load in HIV patients in 
Pengayoman Cipinang Hospital 
 
MATERIALS AND METHOD 
 
This study used a cross-sectional design. The 
population was patients with HIV who were treated 
in Pengayoman Cipinang Hospital in 2015-2018 and 
obtained first-line ARV FDC drugs therapy. Inclusion 
criteria were such as the second stage of HIV 
patients receiving first-line ARV FDC therapy 
(Tenofovir, Lamivudine, and Efavirenz ) for at least 
one year, outpatients, and above 18 years old. 
Meanwhile, the exclusion criteria were HIV patients 
with a background of drug-induced hepatitis. The 
following formula determines the sample size: 
 
  
       (   ) 
  (   )         (   )
 
 
Note: 
n =  sample size              
N =  75 people as the total population             
Z1- /2 = alpha standard deviate, determined with  0.05              
d =  absolute accuracy, determined at 0.01              
P = the proportion of HIV patients who adhered to  
taking ARV drugs, determined by researchers at 0.5               
 
The result of the calculation of sample 
size showed 70 data. Data were collected from the 
medical records written in the HIV treatment 
overview and antiretroviral therapy at Pengayoman 
Cipinang Hospital in 2015-2018. Prior to the data 
collection, the researcher had been granted an 
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approval of the ethical review from the Health 
Research Ethics Commission of the Jakarta Veterans 
National Development University (Ethical Approval 
Number: B/1612/IX/2018/KEPK) and a letter of 
permission from the Head of the Pengayoman 
Cipinang Hospital. The random sampling technique 
was used to retrieve the data. This research was 
conducted at Pengayoman Cipinang Hospital in 
October 2018. 
Research variables were categorized based on 
previous research. The independent variable in this 
study was the level of adherence in taking FDC ARV 
drugs defined as the patients’ adherence to taking 
medication schedules once a day for at least one 
year of treatment. The result of measuring the level 
of adherence was divided into three; namely 1) a 
good level of adherence (≥ 95%); 2) moderate level 
of adherence (80-95%); and 3) poor level of 
adherence (≤80%) . 10 Meanwhile, viral load was the 
dependent variable of this study.  It was defined as 
the amount of virus in the blood and was used as a 
measurement tool to monitor the success of ARV 
therapy. In this study, the viral load was divided into 
two, namely 1) successful therapy (≤400 copies/ml) 
and 2) failed therapy (>400 copies/ml).11      
Data analysis was conducted to obtain a 
description of the characteristics of the study 
subjects, the level of adherence in taking FDC ARV 
drugs to viral load, as well as identifying the 
relationship between the level of adherence in 
taking FDC ARV drugs and viral load on the 
subjects. The Kruskal Wallis test was used to 
determine whether there is a relationship between 
subject characteristics and the level of adherence in 
taking FDC ARV drugs. Furthermore, the cross-tab 
was utilized to identify the overview of the 
adherence level of antiretroviral FDC medication 
on virologic failure (viral load >400 copies/ml). As 
the independent variable (the adherence level in 
taking FDC ARVs) and the dependent variable (viral 
load) in this study are categorical variables, the chi-
square test was conducted to examine the 
hypothesis of the study that there is a correlation 
between the level of adherence in taking ARV FDC 
drugs and viral load. The chi-square test would be 
utilized if there were no cells with an expected 
value of less than five. In other words, cells with an 
expected value of less than five used a chi-square 
exact. 
 
RESULT 
 
In Table 1, it can be seen that the cross-tabs 
data are based on demographic characteristics and 
the adherence level in taking antiretroviral FDC  
 
Table 1. Characteristics of Research Subjects 
  Adherence Levels in 
taking ARV FDC Drugs  
 Variable Good 
(>95%) 
N = 56 
Moderate 
(80-95%) 
N = 8 
Poor 
(<80%) 
N = 6 
p 
Gender 
Male 
Female 
 
94.6 
5.3 
 
87.5 
12.5 
 
100 
0 
 
0.593 
Age (y.o) 
Late adolescence  
Early adulthood 
Late adulthood  
 
8.9 
53.5 
37.5 
 
37.5 
50.0 
12.5 
 
16.6 
83.3 
0 
 
0.003 
Education 
Elementary school 
Middle School 
High school 
College/university 
 
8.9 
17.8 
57.1 
16.0 
 
0 
37.5 
62.5 
0 
 
0 
0 
100 
0 
 
0.515 
Occupation 
Employed 
Unemployed 
 
58.9 
41.0 
 
50.0 
50.0 
 
50.0 
33.3 
 
0.818 
Marital status 
Married 
Widower 
Single 
 
42.8 
14.2 
42.8 
 
37.5 
12.5 
50.0 
 
16.6 
33.3 
50.0 
 
0.688 
Risk factors * 
Heterosexual 
Homosexual 
Injectable drug 
Free sex 
Piercing 
Tattoo 
 
33.9 
7.1 
62.5 
1.7 
3.5 
3.5 
 
50.0 
0 
75.0 
0 
0 
0 
 
50.0 
0 
50.0 
0 
0 
0 
 
0.543 
0.593 
0.631 
0.882 
0.776 
0.776 
* Note: some research subjects have more than one risk factor 
 
drugs. A total of 56 out of 70 (80%) research 
subjects had good adherence (95%). Based on 
gender, the majority of subjects were males with 
good, moderate, or poor levels of adherence. 
Meanwhile, based on age, the majority of subjects 
were early adulthood (26-35 years old), followed by 
late adulthood (36-45 years old) and late 
adolescence (17-25 years old). The educational 
background of the research subject started from 
high school with the most significant number of the 
subjects, followed by university level, junior high 
school, and elementary school. Most of the subjects 
were employers and unmarried with risk factors 
using injecting narcotics, psychotropic substances, 
or additives (NAPZA).  
The result of the Kruskal-Wallis test 
showed there were no differences in the adherence 
level in taking ARV FDC drugs among the groups 
based on gender, education level, marital status, 
employment status, and risk factors for HIV 
infection (p> 0.05). However, there were significant 
differences in the group based on age (p=0.003). 
Table 1 shows that the subjects who were in a poor 
level of adherence in taking ARV FDC drugs (≤ 80%) 
were mostly early adulthood (26-35 years). 
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Figure 1. Virological Failure based on the Adherence Level 
toward ARV FDC Therapy 
 
Table 2. The relationship between the adherence level in 
taking ARV FDC drugs and viral load 
Adherence in 
taking ARV FDC 
drugs 
Viral Load 
Total 
P. 
≤400 
copies
/ml 
>400 
copies/
ml 
N % N % N % 
Good (> 95%) 55 98.2 1 1.8 56 100 
0.000 Moderate (80-95%) 2 25.0 6 75 8 100 
Poor (<80%) 0 0 6 100 6 100 
 
In Figure 1, it can be seen that the adherence 
level in taking ARV FDC drugs influenced 
the percentage of virological failure ( viral 
load >400 copies/ml ). The respondents with a good 
level of adherence (≥ 95%) experienced virological 
failure of 1.8%, which is far less compared to a 
moderate level (80-95%) and poor level of 
adherence (≤ 80%). 
Table 2 shows the result of the exact Chi-
square test, revealing the relationship between the 
level of adherence in taking ARV FDC drugs and viral 
load (p=0.000). 
 
DISCUSSION 
 
Based on gender, out of 70, 66 (94.3%) 
subjects were males. The result is in line with the 
data from the Indonesian Ministry of Health in 
2012,10 showing that males are more likely to live 
with HIV / AIDS than females by a ratio of 
2:1.10  Another study showed 72.3% of 595 subjects 
with HIV / AIDS are males.12 The high proportion of 
males infected by HIV / AIDS is assumed to be 
caused by a large number of males who commit 
risky sexual relationships and use injecting drugs. 
Meanwhile, females are more often infected with 
HIV from their sexual partners. It is supported by 
the result of research at H. Adam Malik General 
Hospital Medan, which revealed that 73% of 163 
research subjects were infected with HIV through a 
risky sexual relationship, the majority of whom are 
males. Furthermore, 77.6% of 58 subjects who were 
at risk of being infected with HIV through blood 
were males.13 Other studies also mention that males 
are more at risk of being infected with HIV / AIDS 
due to negative behaviors carried out, for example, 
using commercial sex services and injecting 
NAPZA.14 
The highest prevalence of HIV / AIDS cases in 
Pengayoman Cipinang Hospital is in the group of 
early adulthood, and late adulthood (26-45 years) 
which is categorized as a productive age. The result 
of other studies also showed that the majority of 
people infected with HIV / AIDS were in the 
productive age range.15 In this study, it was also 
found that there were differences in the adherence 
level in taking ARV FDC drugs based on the age of 
the group members. Subjects with a low level of 
adherence in taking ARV FDC drugs (≤ 80%) mostly 
belong to the group of early adulthood (26-35 
years) (Table 1). Thus, the group needs to be given 
more attention through education and support 
from both medical personnel and families to 
increase their adherence level in taking medicine. 
Based on the level of education, most subjects 
have the most recent High School education level. 
The result of other studies showed that the 
incidence of HIV / AIDS is more common in people 
who have a high level of education.12,14 In general, 
people with higher education have a better level 
of knowledge related to the problem of HIV / AIDS, 
so they are expected that they do not engage in 
risky behavior to become infected with HIV. 
However, the result of this study indicates 
that most subjects are highly educated. It is 
suspected that the social environment becomes the 
major factor of subjects with higher education 
levels infected with HIV. This assumption is 
supported by the result of the research showing 
that sexually transmitted infections, including HIV, 
more frequently occur in groups with high school 
education level and above. In that study, it was 
assumed that the increasing level of economic 
stability and higher education level have an impact 
on the growing use of prostitution services.16    
The research subjects in this study are mostly 
employed. It is in line with other studies that found 
that HIV / AIDS infected subjects were patients who 
were employed.12 A person who works and has 
more income makes it possible to carry out risky 
behavior to be infected with HIV, primarily when an 
inadequate social environment influences it.  
Based on marital status, this study revealed 
that most subjects are unmarried. Other studies 
have also found that people with unmarried status 
>95; 1.8% 
80-95; 
75.0% 
<80; 
100.0% 
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are at risk of being infected with HIV / AIDS.14 The 
riskiest factor for HIV / AIDS infection in this study 
was the use of drug injection. It is in line with data 
indicating that the current spread of HIV is not only 
through a sexual relationship, but also through drug 
injection identified to be able to transmit HIV of 50-
90%.10    
The overview of virological failure by a total of 
56 out of 70 (80%) research subjects had good levels 
of adherence in taking ARV FDC drugs (≥ 95%) 
(Table 1). It is in line with studies suggesting that 
the simpler the ARV drug regimen is, the higher the 
level of the patients’ adherence in taking ARV drugs 
will be. Patients with FDC were twice as much as 
adherence level in taking medication compared to 
those using multiple ARV regimens.4 The adherence 
to medication is a condition in which patients 
adhere to treatment based on their consciousness, 
not only due to their adherence to the doctor's 
command.3   
Disadherence of patients in taking ARV drugs 
can result in therapy failure. In order to achieve a 
good virological suppression, a high level of 
adherence to ARV is highly needed. The result of 
this study showed that to achieve an optimal level 
of viral suppression, at least 95% of all medication 
doses must not be abandoned. The risk of therapy 
failure arises when the patient frequently ignores to 
take medication. Good collaboration between 
health workers and patients, as well as 
communication and constructive treatment 
atmosphere, will raise patients’ adherence to take 
medication.3 Specifically, the result of this study 
shows that the subjects with a good level of 
adherence to ARV FDC medication (≥95%) who 
experienced treatment failure are only 1.8% (Figure 
1). It reveals the effectiveness of the mechanism of 
ARV FDC consisting of Tenofovir, lamivudine, and 
efavirenz to inhibit reverse transcriptase so that the 
viral RNA chain can not be altered into DNA. The 
similar result shows that the ARV FDC regimen plays 
an important role in the HIV suppression. HIV 
patients with good adherence tend to have 
undetectable viral load values. Besides, the result of 
this study also showed that the use of FDC ARV 
could reduce the risk of HIV patients being 
hospitalized by 31% and increase the opportunity of 
an undetectable viral load by 21%.17    
Criteria for the failure of antiretroviral therapy, 
according to WHO (2013),18 are determined by the 
amount of viral load by >400 copies/ml upon one-
year therapy, or the viral load becomes re-
detectable after being undetected. The patients’ 
noncompliance most likely causes the failure of 
therapy in taking ARV.18 The result of this study 
reveals that the subjects with a moderate level of 
adherence (80-95%) experienced treatment failure 
indicated by the virological failure of up to 75%. 
Meanwhile, patients with a poor level of adherence 
(≤ 80%) experienced a 100% treatment failure 
(Figure 1).   
Furthermore, this study also found a 
relationship between the level of adherence to 
taking ARV FDC and viral load (Table 2). It is the 
most important factor in suppressing the number of 
HIV viruses. The long stable viral suppression aims 
to keep the body's immune system high. Thus, 
people infected with HIV will obtain a good quality 
of life and also prevent morbidity as well as 
mortality.6   
In subjects with a good and moderate level of 
adherence, it is necessary to provide constant 
counseling regarding the adherence to taking ARV 
medicine. Based on the therapy guidelines, upon 
adherence counseling, the patient needs to be 
evaluated for three months while taking first-line 
ARVs. If a decrease in viral load reaches the target, 
the conduction of first-line ARVs will remain. 
Conversely, if there is an increase in viral load, the 
therapy is later switched to the second-line ARVs.6,19 
The noncompliance to taking medication allows 
resistance due to mutation. The result of the study 
in HIV patients in West Java found resistance to 
first-line ARV medicine in subjects with virological 
failure (viral load ≥400 copies/ml) upon 6-month 
therapy.12    
In a similar study, virological failure was found 
in 21.7% of HIV patients with an adherence level of 
≥95%, 80-95% of adherence level ranges from 54.6-
66.7%, and <80% reaches >71.4%.11 The difference 
between the result of that study and the result of 
this study can be caused by differences in the drug 
regimen used. The result of the study explained 
above used the protease inhibitors in therapy.11 
Moreover, other possibilities are differences in the 
subtype, sub-sub types, or recombinant forms of 
HIV that infect the subject of the research and that 
the percentage of virological failure is also different 
despite a similar level of adherence in taking 
medication process. The research in East Java 
identifying 30 samples of HIV-1 subtypes showed 
that the subtypes found were mostly a group 
of Circulating Recombinant Forms similar to those 
found in Southeast Asia.20 Besides that, the 
virological failure is also known to be determined by 
an increase in CD4 levels. An increase in CD4 by <50 
cells/mm is an independent predictor of virological 
failure in HIV patients receiving the first-line ARV 
therapy with a good level of medication 
adherence.21 
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This study only utilized the data of medical 
records written in HIV Treatment Overview and 
Antiretroviral Therapy, so that there are undetected 
risk factors that are likely to influence the 
adherence level of ARV FDC, for example, the 
background of alcohol consumption of the research 
subjects. Besides, the medical record did not show 
the HIV subtype as a result of the GenXpert 
examination. Thus, it cannot be further analyzed 
whether differences in HIV subtypes also caused 
virological failure. 
 
CONCLUSION 
 
There was a significant relationship between 
the level of adherence in taking ARV FDC and viral 
load. 
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